Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 8, 2024
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite
Martin E Dowty, Ruolun Qiu, Alyssa Dantonio, et al.
Clinical and Translational Science
|
December 18, 2023
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy
Ruolun Qiu, Kari Fonseca, Arthur Bergman, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
July 24, 2012
Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis
James A Rogers, Daniel Polhamus, William R Gillespie, et al.
Journal of Alzheimer'S Disease : JAD
|
August 20, 2019
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects
Ruolun Qiu, Jae Eun Ahn, Robert Alexander, et al.
The Journal of Investigative Dermatology
|
April 21, 2020
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth B Forman, David M Pariser, Yves Poulin, et al.
Clinical Pharmacology and Therapeutics
|
July 18, 2019
Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies
Jae Eun Ahn, Charles Carrieri, Fernando Dela Cruz, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
March 19, 2024
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design
John D Groarke, Jeffrey Crawford, Susie M Collins, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 17, 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, et al.
The New England Journal of Medicine
|
September 16, 2024
Ponsegromab for the Treatment of Cancer Cachexia
John D Groarke, Jeffrey Crawford, Susie M Collins, et al.
British Journal of Pharmacology
|
December 8, 2017
Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865
Sarah A Nickolls, Rachel Gurrell, Guido van Amerongen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 8, 2024
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite
Martin E Dowty, Ruolun Qiu, Alyssa Dantonio, et al.
Clinical and Translational Science
|
December 18, 2023
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy
Ruolun Qiu, Kari Fonseca, Arthur Bergman, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
July 24, 2012
Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis
James A Rogers, Daniel Polhamus, William R Gillespie, et al.
Journal of Alzheimer'S Disease : JAD
|
August 20, 2019
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects
Ruolun Qiu, Jae Eun Ahn, Robert Alexander, et al.
The Journal of Investigative Dermatology
|
April 21, 2020
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth B Forman, David M Pariser, Yves Poulin, et al.
Clinical Pharmacology and Therapeutics
|
July 18, 2019
Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies
Jae Eun Ahn, Charles Carrieri, Fernando Dela Cruz, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
March 19, 2024
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design
John D Groarke, Jeffrey Crawford, Susie M Collins, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 17, 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, et al.
The New England Journal of Medicine
|
September 16, 2024
Ponsegromab for the Treatment of Cancer Cachexia
John D Groarke, Jeffrey Crawford, Susie M Collins, et al.
British Journal of Pharmacology
|
December 8, 2017
Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865
Sarah A Nickolls, Rachel Gurrell, Guido van Amerongen, et al.
Page
of 3